%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Vergne, Laurence
%A Diagbouga, S.
%A Kouanfack, C.
%A Aghokeng Fobang, Avelin
%A Butel, Christelle
%A Laurent, Christian
%A Noumssi, N.
%A Tardy, M.
%A Sawadogo, A.
%A Drabo, J.
%A Hien, H.
%A Zekeng, L.
%A Delaporte, Eric
%A Peeters, Martine
%T HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon
%D 2006
%L fdi:010056496
%G ENG
%J Antiviral Therapy
%@ 1359-6535
%K BURKINA FASO ; CAMEROUN
%M CC:0002399847-0005
%N 5
%P 575-579
%U https://www.documentation.ird.fr/hor/fdi:010056496
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers19-12/010056496.pdf
%V 11
%W Horizon (IRD)
%X We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n=1], M41L+T69S [n=1]), four to non-NRTIs (NNRTIs; V106A/V [n=1] and V108I [n=3]) and two to protease inhibitors (Pls; L33F [n=2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to Pls (M46I/L [n=2], L33F [n=1]), three to NRTIs (T69N/T [n=1], M184V [n=1], A62V [n=1]) and two to NNRTIs (P236L [n=1], V108I [n=1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.
%$ 052